Newark, New Jersey – May 17, 2022 – BioCentriq is thrilled to announce that we have been acquired by GC, a South Korean company founded in 1967 with a major footprint across healthcare sectors.
As a subsidiary of the New Jersey Innovation Institute, BioCentriq was sold for $73 million after a bid involving over 50 companies. The acquisition and investment by GC in BioCentriq is designed to accelerate and grow BioCentriq’s capacity to deliver superior services to cell and gene therapy companies striving to manufacture products for clinical use.
We are proud to continue our work developing and manufacturing autologous and allogeneic cell therapies and gene therapies with the support of GC behind us.
As we continue under the leadership of CEO Dr. Haro Hartounian, BioCentriq will operate similarly to other GC owned companies. We will maintain our independence as a stand-alone operation and preserve our established identity and culture.
To read the full story on BioCentriq’s acquisition, click here.
